$TWST

Green Paula sold $97K of TWST

Green Paula (SVP of Human Resources) sold 1,133 shares of Twist Bioscience Corp (TWST) at $85.32 on 2026-08-03.

Original reporting
SEC EDGAR · Green Paula
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosure updates the record of insider activity, which can marginally influence sentiment but does not provide new operational or financial information.

02

Market read

A modest insider open-market sale was reported, offering limited incremental trading signal absent other company-specific catalysts.

03

What to watch

The filing does not disclose motivations, and the share count ($96.7k) is small, so traders should avoid over-weighting it versus earnings, guidance, or trial/product catalysts.

Relevance 3/10Novelty 3/10Timing: Form 4 filed 2026-08-05, covering a sale executed 2026-08-03.

Background

The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience SVP of Human Resources Green Paula sold 1,133 shares at $85.3212 on 2026-08-03, disclosed via Form 4 filed 2026-08-05.

Expected impact

Likely limited near-term impact; any effect should be small and short-lived unless follow-on selling emerges.

Evidence & confidence

Form 4 provides transaction details but does not indicate company performance, guidance, or material corporate events. The sale size is modest relative to typical institutional flows, and insider sales are often non-informational.

Market effects

Minimal. Insider sales in biotech tools are not a sector-wide signal from this single filing.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan does not necessarily imply negative information; insiders may sell for diversification, taxes, or planned personal liquidity needs.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale by an SVP of Human Resources.

  • Green Paula

    SVP of Human Resources who sold 1,133 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.